1045-71-2

Basic information

• Product Name: 16-DEHYDROPREGNENOLONE OXIME
• Synonyms: 3-Hydroxypregna-5,16-dien-20-one oxime;5,16-Pregnenolone oxime;Pregn-5,16-dienolone 20-oxime;3BETA-HYDROXY-5,16-PREGNADIEN-20-ONE OXIME;5,16-PREGNADIEN-3BETA-OL-20-ONE OXIME;5,16-PREGNADIEN-3-BETA-OL-20-ONE 20-OXIME;16-DEHYDROPREGNENOLONE OXIME;16-dehydropregnenolone oxime*crystalline
• CAS NO: 1045-71-2
• Molecular Formula: C₂₁H₃₁NO₂
• Molecular Weight: 329.48
• Mol File: 1045-71-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 489.3 °C at 760 mmHg
• Flash Point: 325.2 °C
• Appearance: /
• Density: 1.24 g/cm³
• CAS DataBase Reference: 16-DEHYDROPREGNENOLONE OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 16-DEHYDROPREGNENOLONE OXIME(1045-71-2)
• EPA Substance Registry System: 16-DEHYDROPREGNENOLONE OXIME(1045-71-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1045-71-2(Hazardous Substances Data)

Usage

General Description

16-Dehydropregnenolone Oxime, also known as Glucorticoid Mifepristone Antagonist, is a derivative of pregnenolone, which is used as a precursor in the biochemical synthesis of progesterone. Its original intended use was as a hormone replacement therapy for women in the form of progesterone. It has significant anti-inflammatory and anti-proliferative properties, making it a potential therapeutic agent for a variety of conditions, including cancer and autoimmune disorders. Additionally, it can be used as an emergency contraceptive when administered at high doses.

Upstream product

• 979-02-2 16-dehydropregnenolone acetate 
• 3604-60-2 17alpha-ethynyl-3beta,17beta-dihydroxy-androst-5-ene 
• 19590-22-8 3β-acetoxy-17-cyano-androsta-5,16-diene 
• 23549-24-8 3β-acetoxy-20-hydroxyiminopregna-5,16-diene 
• 1162-53-4 16-dehydropregnenolone 

Downstream Products

• 23549-24-8 3β-acetoxy-20-hydroxyiminopregna-5,16-diene 

Relevant articles and documents

-

-

Proficient synthesis of biologically active pregnane derivatives and its glycoside - Experimental and theoretical approach

Synthesis of a number of pregnane derivatives including the glycoside has been described in detail. These compounds were synthesized by reaction of 3β-acetoxy-5, 16-pregnadiene-20-one, derived from diosgenin and then treating it with different nucleophilic reagents. The structures of these newly synthesized compounds were established on the basis of their physical, chemical and spectral data. The molecular geometry of compounds were calculated in ground state by density functional theory method (DFT/B3LYP) using 6-31G (d,p) basis set. 1H NMR chemical shifts were also studied using gauge-including atomic orbital (GIAO) approach, which were found in good agreement with the experimental values. The study of electronic properties such as UV-Vis spectral analysis, HOMO and LUMO energy calculations were performed with time dependent DFT (TD-DFT). Global and local reactivity descriptors were calculated to study the reactive sites within the molecules. These compounds were also evaluated for their anti-dyslipidemic (Triton model) and in vitro anti-oxidant activities. Out of these, compound 9 showed potent anti-dyslipidemic and anti-oxidant activity.

PREGNANE-OXIMINO-AMINOALKYLETHERS AND PROCESS FOR PREPARATION THEREOF, USEFUL AS ANTIDIABETIC AND ANTIDYSLIPIDEMIC AGENTS

The present invention relates to the synthesis of pregnane-oximino-aminoalkyl-ethers and their antidiabetic and antidyslipidemic activities. More particularly, the invention relates to the synthesis of compounds of formula 3 and biological profile thereof. Further the invention relates to compounds of formula 3 and pharmaceutically acceptable salts thereof.